Icure Pharmaceutical Incorporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 538.24 million compared to KRW 163.59 million a year ago. Net loss was KRW 5,712.87 million compared to KRW 9,609.08 million a year ago. Basic loss per share from continuing operations was KRW 251.6667 compared to KRW 441.6667 a year ago. Diluted loss per share from continuing operations was KRW 251.6667 compared to KRW 441.6667 a year ago. Basic loss per share was KRW 251.6667 compared to KRW 883.3333 a year ago.
For the nine months, sales was KRW 843.4 million compared to KRW 733.02 million a year ago. Net loss was KRW 22,029.06 million compared to KRW 22,129.03 million a year ago. Basic loss per share from continuing operations was KRW 969.1667 compared to KRW 1,016.6667 a year ago. Diluted loss per share from continuing operations was KRW 969.1667 compared to KRW 1,016.6667 a year ago. Basic loss per share was KRW 969.1667 compared to KRW 2,033.3333 a year ago.